Exercise Capacity During Cancer Recovery: Mechanisms, Clinical Implications, and Evidence-Based Management

Abstract

Exercise capacity, a central determinant of functional status and quality of life, is frequently compromised during and after cancer treatment. This review synthesizes recent evidence on the underlying mechanisms, clinical features, diagnosis, management, and guideline-driven recommendations for optimizing exercise capacity in cancer survivors. Emphasis is placed on the pathophysiological alterations resulting from malignancy and its treatment, risk stratification, and practical approaches to rehabilitation, with a focus on improving patient-centered outcomes and addressing the unique needs of this growing patient population.

Introduction

The global cancer survivor population is increasing due to advances in detection and treatment, resulting in improved survival rates. However, survivors commonly experience persistent sequelae, among which reduced exercise capacity is both prevalent and impactful. Exercise capacity, defined as the maximal ability to perform physical activity, influences not only functional independence but also overall prognosis and quality of life. This article reviews the multifaceted determinants of compromised exercise capacity during cancer recovery, synthesizing recent scientific findings, clinical implications, and evidence-based management strategies for healthcare professionals involved in oncologic care.

Epidemiology / Disease Burden

More than 19 million cancer survivors were reported globally in 2023, with projections indicating continued growth. Studies estimate that up to 70% of cancer survivors report diminished exercise tolerance within the first year post-treatment. The burden is notably high among patients treated for breast, lung, hematologic, and gastrointestinal malignancies. Reduced exercise capacity is associated with increased morbidity, risk of recurrence, cardiovascular disease, and all-cause mortality. The epidemiological data underscore the need for systematic assessment and intervention to address this modifiable risk factor in cancer recovery.

Pathophysiology

Multiple interrelated mechanisms underlie reduced exercise capacity following cancer and its treatments. Direct tumor effects may induce cachexia, leading to muscle wasting and altered metabolism. Cytotoxic therapies, including chemotherapy and radiation, can impair mitochondrial function, promote oxidative stress, and damage cardiac and skeletal muscle tissue. Immune checkpoint inhibitors and targeted therapies may precipitate inflammatory myopathies or cardiotoxicity. Furthermore, hormonal therapies can affect muscle mass and vascular function. The central and peripheral nervous systems may also be affected, compounding neuromuscular fatigue. Collectively, these alterations manifest as a reduction in peak oxygen uptake (VO2 max), diminished strength, and premature fatigability.

Risk Factors

Risk factors for impaired exercise capacity in cancer survivors are multifactorial. Patient-specific factors include older age, pre-existing cardiopulmonary disease, baseline physical inactivity, obesity, malnutrition, and comorbidities such as diabetes or chronic kidney disease. Treatment-related determinants include type, intensity, and duration of chemotherapy, exposure to radiation (especially involving the thorax), use of anthracyclines or trastuzumab, and history of stem cell transplantation. Psychosocial factors such as depression, anxiety, and social support also modulate risk and recovery trajectories.

Clinical Features

Patients may present with exertional dyspnea, generalized fatigue, decreased exercise tolerance, and impaired functional independence. Objective findings may include reduced six-minute walk distance, decreased peak VO2 on cardiopulmonary exercise testing (CPET), muscle weakness, and reduced handgrip strength. Other features may involve orthostatic intolerance, impaired balance, and slow gait speed. These clinical manifestations often coexist with psychological symptoms, further complicating the recovery process.

Diagnosis

Comprehensive assessment of exercise capacity in cancer survivors involves a combination of subjective evaluation and objective testing. Tools such as the six-minute walk test (6MWT), CPET, and physical performance batteries are commonly utilized. Baseline and serial assessment of functional status, fatigue scales (e.g., FACIT-F), and patient-reported outcomes are essential. Cardiac and pulmonary evaluations, including echocardiography and spirometry, may be indicated to rule out underlying organ dysfunction. Laboratory investigations should assess for anemia, electrolyte disturbances, and markers of inflammation or muscle injury.

Treatment & Management

Interventions to improve exercise capacity are multidisciplinary, centering on individualized exercise prescription, nutritional support, and management of comorbidities. Supervised aerobic and resistance training programs, tailored to the patient\"s baseline status and treatment history, have demonstrated significant improvements in VO2 max, muscle strength, and fatigue reduction. Early engagement in prehabilitation, even during active treatment, is associated with better outcomes. Nutritional optimization, including adequate protein and caloric intake, is critical to support muscle recovery. Pharmacologic interventions may be considered for anemia, cardiac dysfunction, or neuropathy. Psychosocial support and behavioral interventions address barriers to activity and promote adherence.

Recent Advances / Emerging Therapies

Recent advances include the use of telemedicine and digital health platforms to deliver remote exercise supervision and monitoring, increasing accessibility for cancer survivors. High-intensity interval training (HIIT) and neuromuscular electrical stimulation are being explored as adjuncts for those unable to participate in traditional exercise programs. Molecular approaches targeting mitochondrial dysfunction and muscle regeneration are under investigation. Wearable sensors and artificial intelligence-driven assessment tools are enhancing real-time monitoring and personalization of rehabilitation strategies.

Guideline Recommendations

Major oncology and rehabilitation societies, including the American College of Sports Medicine (ACSM) and National Comprehensive Cancer Network (NCCN), endorse routine assessment of physical function and the prescription of individualized exercise regimens for cancer survivors. Guidelines recommend at least 150 minutes per week of moderate-intensity aerobic activity, combined with two or more sessions of resistance training. Preparticipation evaluation, risk stratification, and multidisciplinary collaboration are emphasized to ensure safety and optimize outcomes. Adaptations should be made based on the patient\"s specific cancer type, treatment exposures, and comorbid conditions.

Conclusion

Exercise capacity is a critical, modifiable determinant of health and quality of life in cancer survivors. Pathophysiological changes induced by malignancy and its treatments necessitate a comprehensive, multidisciplinary approach to assessment and management. Recent advances in exercise science, digital health, and supportive care have expanded the therapeutic arsenal available to clinicians. Adherence to evidence-based guidelines and individualized rehabilitation strategies are essential to optimize recovery, reduce morbidity, and enhance functional independence in this vulnerable population.